Mps One Binder Kinase Activator (MOB)1A/1B are core components of the Hippo pathway that coactivate large tumor suppressor homolog (LATS) kinases. Mob1a/1b double deficiency in mouse liver (LMob1DKO) results in hyperplasia of oval cells and immature cholangiocytes accompanied by inflammatory cell infiltration and fibrosis. More than half of mutant mice die within 3 wk of birth. All survivors eventually develop liver cancers, particularly combined hepatocellular and cholangiocarcinomas (cHC-CCs) and intrahepatic cholangiocellular carcinomas (ICCs), and die by age 60 wk. Because this phenotype is the most severe among mutant mice lacking a Hippo signaling component, MOB1A/1B constitute the critical hub of Hippo signaling in mammalian liver. LMob1DKO liver cells show hyperproliferation, increased cell saturation density, hepatocyte dedifferentiation, enhanced epithelial-mesenchymal transition and cell migration, and elevated transforming growth factor beta(TGF-β)2/3 production. These changes are strongly dependent on Yes-Associated Protein-1 (Yap1) and partially dependent on PDZ-binding motif (Taz) and Tgfbr2, but independent of connective tissue growth factor (Ctgf). In human liver cancers, YAP1 activation is frequent in cHC-CCs and ICCs and correlates with SMAD family member 2 activation. Drug screening revealed that antiparasitic macrocyclic lactones inhibit YAP1 activation in vitro and in vivo. Targeting YAP1/TAZ with these drugs in combination with inhibition of the TGF-β pathway may be effective treatment for cHC-CCs and ICCs.
MOB1 | Hippo pathway | liver cancer | ivermectin | TGF-beta L iver cancer is the third leading cause of cancer death in humans (1, 2) . Hepatocellular carcinoma (HCC) and intrahepatic cholangiocellular carcinoma (ICC) are the first and second most common liver cancers in humans, whereas combined hepatocellular and cholangiocarcinomas (cHC-CCs) occur at rare frequency (3) . For unknown reasons, patients with ICC and cHC-CC have much worse prognoses than HCC patients (3) . Although molecularly targeted agents increase the survival of patients with advanced HCC, ICC and cHC-CC patients rarely show clinical responses to these drugs. Therefore, elucidation of the molecular mechanisms driving the onset/progression of ICCs and cHC-CCs and the identification of targeted agents effective against these tumors are eagerly awaited.
The Hippo signaling pathway was first identified as regulating organ size in Drosophila (4). In mammals, most components of the Hippo pathway have been implicated as tumor suppressors, including neurofibromin-2 (NF2), the mammalian STE20-like protein (MST) kinases, the large tumor suppressor homolog (LATS) kinases, and the adaptor proteins Salvador Homolog-1 (SAV1) and Mps One Binder Kinase Activator (MOB). MOB is considered to be one of four core Hippo pathway components. Structurally, MOB is an adaptor protein with no apparent functional domain. However, phosphorylation of MOB by MST allows MOB to bind to LATS, and this binding greatly increases the phosphorylation and kinase activity of LATS (5) . Downstream of MOB and LATS are two paralogous transcriptional coactivators: YesAssociated Protein-1 (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ), which drive the expression of numerous effector genes (6) .
Activation of the Hippo pathway occurs in response to increased cell density and decreased extracellular matrix rigidity or mechanical forces (7) . In the presence of MOB1, LATS1/2 strongly phosphorylates YAP1/TAZ, which binds to 14-3-3 protein. This binding draws phosphorylated YAP1/TAZ into the cytoplasm (8) ,
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preventing it from activating TEA domain family member (TEAD)-mediated transcription of connective tissue growth factor (CTGF) (9) , secreted phosphoprotein 1 (SPP1) (10) , transforming growth factor beta (TGFβ) (11) , and Jagged 1 (JAG1) (12) . Phosphorylated YAP1/TAZ also binds to E3-ubiquitin ligase SCF βTRCP and is degraded (13) . Thus, YAP1/ TAZ are positive regulators of cell proliferation that are suppressed by Hippo signaling.
Hippo signaling is important for stem cell quiescence. Mice with liver-specific deletion of Nf2 (14) , Sav1 (15, 16) , or Mst1/2 (17, 18) , or mice with transgenic Yap1 expression (19) (20) (21) , show not only liver tumors but also hepatocyte dedifferentiation (22) , increased liver stem/progenitor cells, and hepatomegaly. However, the precise roles of mammalian Hippo signaling components have been difficult to identify, partly because multiple homologs of each element exist. It is not clear why deficiency for almost any one homolog is embryonic-lethal in mice despite the presence of multiple homologs of each element. In addition, the function of a given Hippo component may differ in different tissues or even in different studies. For example, Benhamouche et al. (14) reported that the liver phenotype of Nf2 −/− mice depends on NF2-EGFR signaling rather than on the NF2-MOB1-LATS-YAP1 pathway, but another study found that the Nf2 −/− liver phenotype could be rescued by heterozygous deletion of Yap1 (23) . Similarly, the skin phenotype associated with abnormal Hippo signaling depends on SAV1 (16) and YAP1, but is independent of MST1/2 (24) . Therefore, the in vivo function of each mammalian Hippo pathway component in each tissue must be clarified separately.
In this study, we focused on liver-specific loss of Mob1a/1b. Among seven MOB homologs in humans, only hMOB1A and hMOB1B bind to LATS1/2 and promote their activation (25) . MOB1A and MOB1B share 95% amino acid identity, are substrates of the ubiquitin ligase PRAJA2 (26) , and are commonly decreased in tumors. hMOB1A is mutated in melanoma and breast cancer cell lines and down-regulated in human colorectal, nonsmall cell lung, and skin cancers (27, 28) . Surprisingly, impaired MOB1 phosphorylation occurs in 81% of human liver cancers (17) , and elevated YAP1 is now an independent prognostic marker for these malignancies (29) . In mice, MOB1B can compensate for loss of MOB1A, and vice versa, but loss of both Mob1a and Mob1b is embryonic-lethal (28). Mice partially deficient for Mob1a/1b develop tumors, most often skin cancers (28) . However, the physiological functions of MOB1A/1B in liver are unknown, and the liver abnormalities of NF2-, SAV1-, or MST1/2-deficient mice had been thought to be independent of MOB1A/1B and LATS1/2 (17) .
TGF-βs regulate cell growth, apoptosis, differentiation, and fibrosis (30) . TGF-βs inhibit the proliferation of normal epithelial cells but display both tumor-suppressing and tumor-promoting activities during cancer development (31) . The binding of TGF-β1-3 to TGF-β receptor-2 (TGFBR2) activates TGFBR1, which activates the SMADs pathway transmitting the signal into the nucleus (32) . Nuclear SMAD2/3 activity is enhanced by nuclear translocation of YAP1/TAZ, whereas cytoplasmic YAP1/TAZ prevents the nuclear accumulation of SMADs (33, 34) .
Here, we analyze the role of MOB1A/1B in mouse liver and show that disruption of MOB1 drives hyperplasia of oval cells and immature cholangiocytes, as well as the development of cHC-CC and ICC in a manner inhibited by the targeting of YAP1/TAZ and TGF-β-SMADs. Importantly, we identify two well-tolerated, antiparasitic macrocyclic lactones as effective YAP1 inhibitors in vitro and in vivo.
Results
Loss of Mob1a/1b in Murine Liver Results in Hyperplasia of Oval Cells/ Immature Cholangiocytes and Early Lethality. We generated liverspecific Mob1a/1b-deficient mice (LMob1DKO mice) by crossing Mob1a flox/flox ;Mob1b −/− mice to AlbCre-Tg mice (35) . Southern blotting confirmed disruption of the Mob1a flox allele in most liver cells of LMob1DKO mice, leaving the Mob1a Δ allele (Fig. S1A ). Crossing of LMob1DKO mice with Rosa26-LSL-YFP reporter mice (36) confirmed that most cholangiocytes and hepatocytes had undergone Mob1a/1b deletion, as determined by YFP-positivity and PCR analysis following laser microdissection ( Fig. S1 B and C) .
From postnatal day (P) 10 (P10) onward, LMob1DKO mice displayed abdominal swelling due to massive hepatomegaly ( Fig. 1  A and B) . The total number of liver cells in LMob1DKO mice was five times that in controls at P14 (Fig. 1C) . The first LMob1DKO mice died at P14, and more than half were dead by P21 (Fig. 1D ). The skin of the mutant mice was jaundiced, and their serum was yellow in color due to elevated bilirubin ( Fig. 1E and Fig. S1D (Fig. S2 A and B) . Immunostaining revealed that the cholangiocyte-like cells abundant in LMob1DKO liver expressed the cholangiocyte lineage markers KRT19, KRT7 and CDH1, and that some also bore the oval cell markers A6, TACSTD2, and DLK (Fig. 1G) . Oval cells, which are stem/progenitor cells of hepatocytes and cholangiocytes (37) , are not observed in healthy adult liver but appear in response to liver injury (38) . Immature AFP + hepatocytes were also present in LMob1DKO liver, as were infiltrating inflammatory cells and fibrosis (Fig. 1H) . However, because the oval cell/cholangiocyte accumulations occurred in portal and intraductal locations where oval cells usually reside (39) , and did not form a tumor mass at P14, LMob1DKO livers were deemed to exhibit "oval cell and immature cholangiocyte hyperplasia."
Surviving LMob1a/1a KO Mice Succumb to cHC-CCs and ICCs. Most LMob1DKO mice surviving beyond P21 exhibited mild hepatocholangiocellular hyperplasia. Although these animals had a long lifespan, they all eventually developed hepatocellular adenomas, HCCs, ICCs or cHCC-CCs (Fig. 2) . About 80% (8/10) of surviving LMob1DKO mice showed these tumors by age 15 wk, and all such mutants were dead by 60 wk due to multifocal cHC-CCs (59%; 13/22) (Fig. 2C) , and occurrences of HCC and ICC within the same liver (Fig. 2B) , resembled cases of human cHC-CC and so were classified as cHC-CCs. About 15% (2/13) of tumor-bearing mutants >40 wk of age showed lung metastasis (Fig. 2C) + (hepatocyte nuclear factor-4 alpha) hepatocytes (three times control levels) of LMob1DKO mice (Fig. 3A) , but TUNEL + apoptotic cells were very rare both in control and LMob1DKO liver (Fig. S3A) .
We (Fig. S3C ). imMob1DKOLP cells undergo biliary cell differentiation when cultured in collagen-1 gel containing TNFα but become hepatocytes when cultured in matrigel containing Oncostatin M (Fig. S3 D and E) . After Tmx administration (+Tmx; induces Mob1a/1b deletion), the proliferation and saturation density of imMob1DKOLP cells increased ( Fig. 3B) with no difference in cell size (Fig. S3F) , suggesting that imMob1DKOLP+Tmx cells have a defect in cell contact inhibition. Moreover, these cells formed numerous multilayered foci after prolonged culture (Fig.  3C ) and rapidly generated tumors in vivo after xenografting into nude mice (Fig. S3G) .
RT-PCR examination revealed that imMob1DKOLP+Tmx cells showed increased mRNA levels of the stem cell markers Tacstd2 and Dlk1 and the cholangiocellular markers Krt7, Krt19, Intb4, and Aqp1 but decreased mRNA levels of the mature hepatocyte markers Hnf4α, Alb, Ttr, and Tat ( cloned cell line maintained a homogeneous cell shape and uniform staining, we speculated that the increase in immature cells in LMob1DKO liver might be due to hepatocyte dedifferentiation into oval cells and immature cholangiocytes.
RT-PCR examination of P14 LMob1DKO liver cells showed enhanced expression of mesenchymal cell markers (Vim, Acta2, S100a4, and Des) and transcriptional factors (Zeb1, Snal1, and Twist2) important for the epithelial-mesenchymal transition (EMT) ( (Fig. 3F ). In addition, the migration of imMob1DKOLP+Tmx cells in Transwell chambers was enhanced compared with imMob1DKOLP-Tmx cells (Fig. 3G) . Finally, although not statistically significant, expression levels of epithelial markers such as Cdh1 and Tjp1 tended to be decreased in LMob1DKO liver compared with controls ( Fig. S3H ). This lack of significance may be due to the limited area of enhanced EMT present in LMob1DKO liver. In any case, our data suggest that elevated cell proliferation, impaired contact inhibition, augmented dedifferentiation, enhanced EMT, and increased cell migration may underlie the higher numbers of oval cells/immature cholangiocytes and liver tumor development seen in LMob1DKO mice.
Enhanced YAP1/TAZ and TGF-βs Activation in Mob1a/1b-Deficient Liver Cells. We next investigated the effects of Mob1a/1b loss on Hippo components using imMob1DKOLP cells cultured at high density to achieve saturation. As expected, imMob1DKOLP+Tmx cells showed reduced phosphorylation of YAP1 (Ser127) and TAZ (Ser89) and increased total YAP1 and TAZ proteins under these culture conditions (Fig. 4A ). Quantitative RT-PCR analysis established that these changes were not due to altered YAP and TAZ mRNA levels (Fig.  S4A ). Phospho-LATS1 (T1079) was below the assay detection limit but total LATS1 was reduced in imMob1DKOLP+Tmx cells (Fig.  4 A and B) . No differences in phospho-MST1, total MST1, or total SAV1 were detected. We then stimulated imMob1DKOLP ± Tmx cells with okadaic acid (OA), which activates MST1/2 (40) , and performed immunoblotting after adjusting lysates to equality of LATS1 protein. Whereas OA-stimulated imMob1DKOLP-Tmx cells showed vigorous LATS1 phosphorylation, OA-stimulated imMob1DKOLP+Tmx cells did not (Fig. 4B) .
imMob1DKOLP-Tmx cells cultured at high cell density showed cytoplasmic localization and inactivation of YAP1, as expected (Fig.  4C ). However, YAP1 remained activated and positioned in the nucleus in high-density imMob1DKOLP+Tmx cells. Similarly, most oval cells/immature cholangiocytes and hepatocytes in LMob1DKO livers showed nuclear YAP1, unlike controls (Fig. 4D) . Thus, MOB1 promotes density-induced cytoplasmic localization of YAP1, and MOB1A/1B deficiency drives nuclear localization of YAP1.
We compared control and LMob1DKO livers using microarray and found a greater than fivefold increase in several growth factors and chemokines. High mRNA levels of Ctgf, Spp1, Jag1, Tgfb2/3, and Ccl2, which are all downstream YAP1/TAZ transcriptional targets, occurred in MOB1A/1B-deficient liver (Fig. 4E ). Immunoblotting confirmed up-regulation of these proteins (except CCL2) in LMob1DKO liver, as well as elevation of phospho-SMAD2 (Fig. 4F ). However, activated NOTCH1 (NOTCH1IC), NOTCH2IC, and their downstream target HES1, which are all important for the conversion of hepatocytes into primitive ductular cells (41), were not altered even though JAG1 (Notch ligand) was increased (Fig. 4F) . Immunostaining of Mob1a/1b-deficient livers revealed that CTGF, JAG1, and SPP1 ( Fig. 4G) , as well as phospho-SMAD2 and nuclear SMAD2/3 ( Fig. 4H) , were all enhanced in oval cells/immature cholangiocytes. TGF-β2/3, phospho-SMAD2, and nuclear SMAD2/3 were increased in mutant hepatocytes, and TGF-β3 was also elevated in inflammatory cells. Thus, heightened activation of YAP1/TAZ, CTGF, TGF-βs-SMADs, JAG1, and SPP1 may contribute to the abnormalities in LMob1DKO liver. Alternatively, the observed increase in growth factors such as CTGF, JAG1, and SPP1, especially in immature cholangiocytes, may be secondary to the increased number of oval cells in LMob1DKO liver.
Mob1a/1b-Deficient Liver Phenotypes Depend on YAP1, TAZ, and TGF-βs. To determine whether Mob1a/1b-deficient liver phenotypes depended on activation of YAP1/TAZ, TGF-βs-SMAD2/3, and/or CTGF, we generated triple knockout (TKO) mice: Mob1a/1b plus Yap1 (AlbCre;Mob1a ;Rosa26-LSL-YFP (LMob1DKO-YFP) mice (n = 4). (G) Cell migration assay of imMob1DKOLP cells ± Tmx (1μM) determined using a Transwell assay. The number of cells that had migrated into the bottom chamber after 24 h was counted in four fields under light microscopy. Data are the mean ± SEM (n = 3 chambers per group). *P < 0.01.
plus Ctgf (AlbCre;Mob1a flox/flox ;Mob1b −/− ;Ctgf flox/flox ). The increases in liver weight, numbers of oval cells/immature cholangiocytes, and liver fibrosis seen in LMob1DKO mice were dramatically suppressed by additional Yap1 loss (Fig. 5 A and B) . However, at P14, these triple mutants still exhibited some oval cell/cholangiocellular hyperplasia and fibrosis, indicating that Yap1 deletion cannot rescue the LMob1DKO phenotype completely. All LMob1a/1b;Yap1 TKO mutants survived for at least 20 wk without developing liver cancers, whereas >80% of LMob1DKO mice show tumors or lethality by this age (Fig. 1D ). LMob1a/1b; Taz TKO (Fig. 5C ) and LMob1a/1b;Tgfbr2 TKO (Fig. 5D ) mice displayed partial suppression of abnormalities associated with Mob1a/1b loss. However, LMob1a/1b;Ctgf TKO (Fig. 5E ) mice showed the same range of liver abnormalities as LMob1DKO mice. Thus, the liver phenotypes of LMob1DKO mice are strongly dependent on YAP1 and partly dependent on TAZ and TGF-βs, but not significantly dependent on CTGF.
Because YAP1 and TAZ are coactivators of TEAD1-4, we suspected that the proliferation occurring in the absence of MOB1A/1B was TEAD-mediated. siRNA analysis of imMob1DKOLP+Tmx cells showed that their enhanced proliferation was suppressed by treatment with siYap1/Taz or siTead1/4 ( Fig. S4 B-E) . Addition of TGF-β2 did not alter the proliferation of imMob1DKOLP+Tmx cells but did increase their expression of mesenchymal/cholangiocyte markers while decreasing hepatocyte markers, consistent with a previous report (42) and their enhanced YAP1 activation (Fig. S5  A-D) . In LMob1a/1b;Tgfbr2 TKO mice, the additional loss of Tgfbr2 decreased the YAP1 activation induced by Mob1a/1b deficiency in vivo (Fig. S5 E and F) . Consistent with this observation, treatment in vitro of imMob1DKOLP+Tmx cells with the TGF-βRI inhibitor SB431542 also decreased YAP1 activation (Fig. S5G) .
Thus, considering that (i) TGF-βs production is increased by YAP1/TAZ activation (11), (ii) nuclear SMAD2/3 activity is enhanced by nuclear translocation of YAP1/TAZ (33) , and (iii) YAP1 is activated by TGF-βs, we believe that the TGF-β pathway contributes to YAP1 activation via a positive feedback loop. The elevated TGF-β2 and TGF-β3 in LMob1DKO liver may promote EMT and drive hepatocyte dedifferentiation toward immature cholangiocytes, and it is these cells that invade the liver parenchyma.
YAP1 and TGF-βs-SMADs in Human cHC-CCs and ICCs and Drugs
Targeting Hippo Signaling. Abnormalities in Hippo components occur in many types of human tumors (43) . We immunostained liver samples from patients with cHC-CC, ICC, or HCC to detect YAP1 and SMAD2 and observed significant YAP1 activation (greater than grade 2, as defined in Table S1 ) in 70% of cHC-CCs and 60% of ICCs, but in only 23% of HCCs, 14% of nontumorous cholangiocytes (NT-Chol), and 6% of nontumorous hepatocytes (NT-Hep) (Fig. 6A) . Furthermore, YAP1 activation showed a significant correlation with SMAD2 activation in these cHC-CCs and ICCs (Fig. 6B) .
We next investigated whether chemical compounds or natural products able to inhibit YAP1 might have anticancer effects in the liver. To visualize Hippo pathway activity, we devised a sensitive system based on the H1299 human lung cancer cell line, in which endogenous YAP1 is highly activated. We engineered H1299 cells to express 10 copies of the CTGF TEAD-binding sequence plus the luciferase reporter gene (Fig. S6A) compounds and 10,240 synthetic compounds. Ivermectin (Fig.  S6B ) and its derivative milbemycin D (Fig. S6C) were identified as potential YAP1 inhibitors. Ivermectin is a well-tolerated antiparasitic macrocyclic lactone commonly used to treat river blindness (44) , and both ivermectin and milbemycin D activate glutamategated chloride channels (45) . Treatment of our modified H1299 cells in vitro with ivermectin or milbemycin D inhibited YAP1/ TAZ activity and decreased CTGF expression in a dose-dependent manner ( Fig. 7 A-C and Fig. S6 D-F) . Dasatinib, a c-YES inhibitor that reduces YAP1 nuclear localization and activation, served as a positive control for these experiments. Ivermectin and milbemycin D also strongly suppressed the in vitro growth of both imMob1DKOLP+Tmx cells and an NF2-deficient human mesothelioma cell line (NCI-H290) in which YAP1/TAZ is constitutively activated (Fig. 7 D and E and Fig. S6G ). Cell growth inhibition by ivermectin was similar to that observed following application of siYAP1/TAZ (Fig. 7 D and E) . Importantly, ivermectin treatment of LMob1DKO mice for 5 d (P4-P8) reduced their hepatomegaly, accumulations of oval cells/immature cholangiocytes, excessive hepatic YAP1 activation (Fig. 7 F and G) , and expression of YAP1/TAZ target proteins (Fig. 7H) . Tmx cells into nude mice (Fig. S6H) . These results suggest that antiparasitic macrocyclic lactones may aid in the treatment of liver cancers by blocking Hippo signaling.
Discussion
We have shown that loss of Mob1a/1b in mouse liver results in YAP1/TAZ activation and either early lethality associated with oval cell/immature cholangiocyte hyperplasia or later lethality associated with liver tumorigenesis. These data indicate that MOB1A/1B maintain oval cell quiescence and function as potent tumor suppressors in the liver. The liver phenotypes of LMob1DKO mice are more dramatic than those of mice with liver-specific mutations of Nf2 (14) are the mean ± SEM *P < 0.05, **P < 0.01. N.S., not significant.
effects than TEAD2/3 on transcriptional targets in human liver cells (12) . Finally, we have demonstrated that TAZ and TGF-β2/3 are also critical Hippo signaling effectors whose loss mitigates the liver phenotypes of LMob1DKO mice. We propose a model (Fig. S7A ) in which loss of Mob1a/1b activates YAP1, resulting in impaired cell contact-dependent growth inhibition but increased hepatocyte dedifferentiation, oval cell proliferation, cell migration, EMT, and liver tumor formation. The increased oval cells/immature cholangiocytes and fibrosis in LMob1DKO liver depend partially on increased TGF-β2/3 production by hepatocytes. Indeed, TGF-βs impair hepatocyte lineage differentiation, promote cholangiocyte lineage differentiation (42, 46) , and increase EMT (30) . Because SPP1 (osteopontin) produced by cholangiocytes also drives inflammatory cell infiltration, fibrosis, and cholangiocyte differentiation (47) , some Mob1a/1b-deficient liver phenotypes may depend in part on SPP1 overexpression.
MOB1A/1B binding strongly augments LATS1/2 kinase activities (25) . However, LATS1/2 had been considered unlikely to play a major role in mammalian liver because liver-specific loss of MST1/2 had no effect on LATS1/2 phosphorylation (18), and neither LATS1 KO nor liver-specific LATS2 KO mice show obvious liver phenotypes. More recently, it has been reported that AlbCre;Lats1 flox/flox ;Lats2 flox/flox mice display liver abnormalities that are strikingly similar to those of our LMob1DKO mice (48) , indicating that the MST-MOB1-LATS-YAP1 axis is important after all in mammalian liver.
In human cHC-CCs and ICCs, we observed frequent and strong YAP1 activation that correlated with increased SMAD2 activation. Nuclear translocation of YAP1/TAZ increases transcription of TGF-βs (11), and TGB-βs can activate and increase nuclear YAP1 via SMAD2/3 activation (Fig. S5 C and D) . In addition, nuclear translocation of YAP1/TAZ enhances nuclear translocation of SMAD2/3 (33). These observations suggest that positive cross-talk exists between the TGF-β-SMAD and YAP1/ TAZ pathways (Fig. S7B) , providing signaling that may contribute to the phenotypes of both LMob1DKO mice and patients with cHC-CC or ICC. Because TGF-β2/3 are transcriptional targets of YAP1/TAZ, abnormal elevation of YAP1/TAZ both increases production of TGF-β2/3 and stimulates SMAD-mediated transcription of TGF-β2/3 target genes. Coordinated targeting of YAP1/TAZ and TGF-β signaling may thus be an effective treatment for cHC-CCs and ICCs displaying dysregulated Hippo signaling.
Our library screen revealed that ivermectin (44) and milbemycin D inhibit YAP1 activity in vitro and in vivo. In parasites, these agents kill by activating glutamate-gated chloride channels and inducing membrane hyperpolarization. In mammalian cells, high concentrations of ivermectin not only activate chloride channels but also induce reactive oxygen species accumulation, block the β-catenin pathway, and inhibit the tumor-suppressive activity of PAK kinase (49) (50) (51) (52) . In addition, in virus-infected cells, ivermectin impairs the nuclear import of signaling molecules mediated by α/β importins (53) . This inhibition of nuclear import may not only prevent nuclear localization and activation of YAP1 but perhaps also that of other targets that could contribute to hepatocarcinogenesis. Although the precise mechanism(s) underlying ivermectin's inhibition of YAP1 is not yet clear, this agent does not seem to strongly activate MST, MOB, or LATS (Fig. S8) , indicating that the effect may not be due to interference with canonical Hippo signaling. Nevertheless, it is relevant that, even at high doses, ivermectin has very few adverse effects on humans (49) . This benign profile could potentially accelerate the testing of this agent for cHC-CC or ICC treatment in patients.
In conclusion, our results demonstrate that (i) MOB1A/1B constitute the most important hub of Hippo signaling in mammalian liver, restricting liver cell growth and maintaining hepatocyte stem/progenitor cell quiescence; (ii) the phenotypes of LMob1DKO mice are largely dependent on YAP1 and partly dependent on TAZ and TGF-β2/3; (iii) loss of MOB1A/1B (activation of YAP1) is an important driver of liver tumorigenesis, especially cHC-CCs and ICCs, in both mice and humans; and (iv) antiparasitic macrocyclic lactones inhibit YAP1 activation in vitro and in vivo. Our data point to a new therapeutic approach for cHC-CC and ICC patients based on inhibition of MOB1-YAP1/TAZ and/or TGF-βs-SMADs signaling.
Materials and Methods
Mice. Base mouse strains used in this study were as follows: AlbCre-Tg ;Mob1b −/− mice without the AlbCreTg allele were usually chosen to serve as controls. The deletion frequency of the Mob1a flox allele was confirmed by genomic Southern blotting using the probe indicated in Fig. S1A . Primers used for genotyping PCR are listed in Table S2 . The frequency of Mob1A deletion in hepatocytes and cholangiocytes (Fig. S1C) was determined by PCR analysis of cells microdissected using a Leica LMD6000 instrument.
To visualize cells with Mob1a/1b deletion, LMob1DKO mice were crossed to Rosa26-LSL-YFP reporter mice. To induce Cre-mediated deletion of Mob1a/1b in liver cells of adult mice, we generated AlbCreER;Mob1a Southern Blotting. Genomic Southern blots were performed as described (60) . Agarose gels were transferred to nylon membranes (GE Healthcare) and hybridized to the probe described in Fig. S1A .
Isolation of Mouse Liver Cells. Hepatocytes were isolated from mice on various days after birth using an in situ two-step collagenase liver perfusion method as previously described (61) . Residual liver cells containing Glisson's sheath were further exposed to 0.05% collagenase/ 0.1% Pronase for 30 min to generate a single-cell suspension. This suspension was mixed with the isolated hepatocytes to create a preparation deemed to be "total liver cells," which was used for analysis of total cell numbers and for primary cultures.
Liver Histology. Liver tissues were fixed in phosphate-buffered 4% (wt/vol) paraformaldehyde (PFA) and embedded in paraffin, and sections (5 μm) were mounted on slides for H&E staining or immunohistochemical (IHC) analysis. IHC analysis was performed using the antibodies (Abs) and protocol described below. Liver tissues were also stained using Elastica Masson and Sirius Red according to standard protocols.
Immunostaining. Tissues were fixed in 4% (wt/vol) PFA or neutral-buffered 10% (vol/vol) formalin and embedded in paraffin, or fixed in 1% (wt/vol) PFA and snap-frozen in optimal cutting temperature compound and sectioned (5 μm). observation period. Mice were killed when they became morbid (humane endpoint). The onset of liver tumors was confirmed by macroscopic analysis, and sections of tumors were prepared for H&E staining. mice (without Tmx) using the collagenase perfusion technique described above. Liver cells were cultured (3 × 10 5 per 6-cm dish) in Williams' Medium E (Sigma)
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supplemented with 10% (vol/vol) FCS. The medium was changed twice per week and the culture was maintained for 3 mo until a single spontaneously transformed colony appeared. This colony was isolated, recloned using limiting dilution, and expanded to generate the imMob1DKOLP cell line. Inducible loss of Mob1a/1b in these cells was confirmed by treating them with Tmx (1μM) for at least 5 d, followed by analyses of mRNA expression by RT-PCR and protein expression by immunoblotting.
To induce hepatocyte differentiation, imMob1DKOLP cells (500 cells per 20 μL) were cultured for 2 d using the hanging drop method, followed by culture for an additional 9 d in multiwell plates that were coated with Matrigel (BD Bioscience) and filled with serum-free Williams' Medium E containing 1 μM dexamethasone and 10 ng/mL OncostatinM (R&D). To induce cholangiocyte differentiation, imMob1DKOLP cells (500 cells per 20 μL) were precultured in hanging drops and then cultured for 14 d in 3D cultures (63) containing 0.24 mg/mL type I collagen (Cellmatrix type I-A; Nitta Gelatin), 10% (vol/vol) FCS, and 10 ng/mL TNFα (R&D). ;Mob1b −/− (LMob1DKO) and control mice at P14, using RNAiso (Takara) according to the manufacturer's protocol. Total RNA (1 μg) was reverse-transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche) after DNase (Toyobo) treatment. Sequences of specific primer sets used for RT-PCR are listed in Table S3 . The mRNA level of a specific gene in the mutant was expressed as the fold increase over the corresponding control value.
Immunoblotting. Immunoblotting was carried out using a standard protocol and primary Abs recognizing: pMST1/2 (3681; Cell Signaling), MST1 (3682; Cell Signaling), MOB1A/1B (13730; Cell Signaling), pYAP1 (4911; Cell Signaling), YAP1 (4912; Cell Signaling), pTAZ (sc-17610; Santa Cruz), TAZ (4883; Cell Signaling), pLATS1 (9159; Cell Signaling), LATS1 (3477; Cell Signaling), CTGF (sc-14939; Santa Cruz), SPP1 (AF808; R&D), JAG1 (sc-8303; Santa Cruz), TGF-β2 (ab36495; Abcam), TGF-β3 (BS1363; Bioworld Technology), CCL2 (NBP2-22115S; Novus), NOTCH1 IC (ab8952; Abcam), NOTCH2 IC (ab8926; Abcam), HES1 (ab71559; Abcam), pSMAD2 (AB3849; Millipore), SMAD2/3 (sc-8332; Santa Cruz), ACTIN (A2066; Sigma), or GAPDH (sc-25778; Santa Cruz). Primary Abs were detected using HRPconjugated secondary Abs (Cell Signaling).
Cell Migration. Migration of imMob1DKOLP cells was assayed using Transwell chambers (5-μm pore size; Costar). imMob1DKOLP cells precultured with or without Tmx (1μM) for 6 d were seeded in the upper Transwell chamber in 0.5% BSA/Williams' Medium E (1 × 10 4 cells per well), and 10% (vol/vol) FCS/Williams' Medium E was added to the bottom chamber. After 24 h, cells remaining in the upper chamber were removed and cells in the bottom chamber were fixed with 4% (wt/vol) PFA, stained with crystal violet, and counted under a light microscope. Four fields per chamber were evaluated.
siRNA Transfection. siRNA targeting of Yap1, Taz, Tead1, Tead2, Tead3, Tead4, Smad2, or Smad3 expression was performed using the specific siRNA oligonucleotides listed in Table S4 . Transfection of siRNA oligonucleotides (10 nM) into exponentially-growing imMob1DKOLP cells or NF2-deleted NCI-H290 human mesothelioma cells (64) (3 × 10 4 per well in 24-well plates) was performed using Lipofectamine RNAiMAX (Invitrogen) following the manufacturer's protocol. At 72 h posttransfection, total cell numbers were evaluated and total RNA was subjected to RT-PCR to detect inhibition of mRNA expression.
Clinical Samples. Surgically obtained human cHC-CCs (n = 30), ICCs (n = 30), and HCCs (n = 30) were acquired from the Department of Surgery of Kyushu University Beppu Hospital and affiliated hospitals. Resected cancer tissues were fixed in formalin and stained with anti-YAP1 Ab (WH0010413M1; Sigma) or anti-SMAD2 Ab (sc-101153; Santa Cruz) using a standard protocol.
Resected nontumorous healthy cholangiocytes (n = 30) and hepatocytes (n = 30) were examined as controls. Grades of YAP1 and SMAD2 activation were defined as described in Table S1 . The clinical sample study design was approved by the Kyushu University Institutional Review Board for Clinical Research and informed consent was obtained from each patient.
Chemical Screening. H1299 cells were engineered to express a reporter construct containing 10 copies of the TEAD-binding sequence from the CTGF gene plus the firefly luciferase gene ( ), were injected s.c. into the flanks of 8-to 10-wk-old female BALB/cAJcl-nu/nu mice (CLEA Japan). After visual detection of tumors (usually by 8 d postinjection), mice were treated with 45% (wt/vol) cyclodextrin-conjugated ivermectin (10 mg/kg, i.p., daily) or cyclodextrin carrier alone and supplied with normal drinking water or water containing Dox (2 mg/mL). Tumor volumes were measured every 2 d using calipers.
Statistics. Where appropriate, results are expressed as the mean ± SEM of the indicated number of mice or cultures per group. Statistical differences were determined using the Student's t test or Welch's t test. Survival curves were calculated using the Kaplan-Meier method and analyzed with the log-rank test. For clinical samples, statistical differences between groups were determined using the χ 2 test and the JMP software package (SAS Institute).
Supporting Information
Nishio et al. 10 .1073/pnas.1517188113 Immunoblotting (E) and immunostaining (F) to detect YAP1 and SMAD2/3 activation in livers of control, LMob1DKO, and LMob1DKO;Tgfbr2 TKO mice (n = 4 per group). GAPDH in E is loading control. (Scale bars in F, 20 μm.) (G) Immunoblotting to detect YAP1 and SMAD2/3 activation in imMob1DKOLP cells that were pretreated (+) or not (−) with Tmx (1 μM) in vitro and then cultured for 60 min with TGF-β2 (10 ng/mL) plus DMSO (vehicle) or SB431542 (10 μM). For all panels, results shown are representative of at least three independent trials. Model of a molecular explanation for the phenotypes observed in Mob1a/1b-deficient liver. MOB1 deficiency increases the production of cytokines such as TGF-β2,3 and SPP1, which increase fibrosis and inflammatory cells in the liver. Liver damage by fibrosis and inflammatory cells ensues that induces the appearance of oval cells. Activation of YAP1 in oval cells in the absence of MOB1A/1B stimulates cell proliferation, impairs contact inhibition, promotes dedifferentiation resulting in stem/progenitor cell maintenance, and facilitates oval cell infiltration by EMT throughout the liver. TGF-β2,3 also positively regulate YAP1 activation, and the increased TGF-β2,3 and SPP1 present promote a lineage shift from hepatocytes to cholangiocyte-like cells. Under the continuing influence of highly activated YAP1/TAZ, these oval cells and immature cholangiocytes continue to proliferate and eventually undergo malignant transformation. Liver tumors, particularly cHC-CCs and ICCs, are then generated in LMob1DKO mice and soon show enhanced EMT invasion. (B) Cross-talk between the YAP1/TAZ and TGF-βs-SMADs signaling pathways. Engagement of the TGF-βR complex by TGF-β2/3 leads to SMAD2/3 activation, interaction with SMAD4, and translocation of the SMAD complex into the nucleus, where it activates transcription of TGF-β2/3 target genes. Engagement of GPCR inhibits the Hippo pathway leading to YAP1/TAZ activation, a process inhibited by contact inhibition. Nuclear translocation of activated YAP1/TAZ both increases TEAD-mediated transcription of TGF-βs and enhances nuclear translocation of SMAD2/3. Reciprocally, TGF-β2/3-mediated activation of SMAD2/3 may activate YAP1/TAZ and promote its nuclear translocation. Thus, positive cross-talk is observed between the TGF-βs-SMADs pathway and YAP1/TAZ signaling. YAP1 or SMAD2 activity grades 0-4 were defined by multiplying frequency score by intensity score. 
